Pharmaceutical Product Development (PPD) announced it was awarded a seven-year contract under the Clinical Research Support Services (CRSS) program of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.

The CRSS critical infrastructure contract provides support for assessing and auditing investigative sites and laboratories, capacity building, biostatistics, site training and data management. PPD will provide a broad range of clinical and other related research support services for the NIAID/DAIDS-supported clinical research portfolio and other infectious diseases relevant to HIV-infected and at-risk populations.

“We are pleased to help NIAID develop and maintain a strong clinical infrastructure to meet the needs of DAIDS’ scientific agenda,” said William Sharbaugh, chief operating officer of PPD. “Our dedicated professionals are committed to supporting the agencies’ initiatives to improve health.”

This agreement complements a long-standing collaboration between PPD and NIAID that, in March, was extended through 2024, covering support for a broad scope of research related to HIV or HIV co-infections.